Monoclonal antibodies in the treatment of autoimmune diseases
Article Sidebar
Publicado
sep 28, 2023
##plugins.pubIds.doi.readerDisplayName##
https://doi.org/10.36677/medicinainvestigacion.v11i2.20348
Main Article Content
Jesús Emiliano García Aguilar
http://orcid.org/0009-0003-8623-9222
Andrea Castillo Ramírez
http://orcid.org/0009-0005-6515-3483
Yolanda Cruz Martínez
http://orcid.org/0000-0002-4536-5674
http://orcid.org/0009-0003-8623-9222
Andrea Castillo Ramírez
http://orcid.org/0009-0005-6515-3483
Yolanda Cruz Martínez
http://orcid.org/0000-0002-4536-5674
Resumen
Autoimmune diseases are a group of pathologies characterized by the presence of autoantibodies and the loss of immunological tolerance towards self-antigens. Although it is difficult to establish the incidence and prevalence, it is estimated that only 3% of the population in the United States suffers from any of them.
There are different therapeutic routes to tackle this class of diseases, highlighting biological therapies, one of them being monoclonal antibodies (MAbs). There are different therapeutic routes to address this class of diseases, highlighting biological therapies, one of them being monoclonal antibodies (MAbs). These are therapeutic agents with additional advantages in selectivity, availability and function related to small molecules and peptides. MABs are developed and approved for the treatment of diseases related to different systems such as nervous, cardiovascular, immunology, among others. This mini review summarizes the applications of monoclonal antibodies in autoimmune diseases with affections in the nervous system, focusing mainly on FDA approved monoclonal antibodies products that are currently available in the market.
##plugins.generic.usageStats.downloads##
##plugins.generic.usageStats.noStats##
Article Details
Como citar
GARCÍA AGUILAR, Jesús Emiliano; CASTILLO RAMÍREZ, Andrea; CRUZ MARTÍNEZ, Yolanda.
Monoclonal antibodies in the treatment of autoimmune diseases.
Medicina e Investigación Universidad Autónoma del Estado de México, [S.l.], v. 11, n. 2, p. 86-93, sep. 2023.
ISSN 2594-0600.
Disponible en: <https://medicinainvestigacion.uaemex.mx/article/view/20348>. Fecha de acceso: 03 oct. 2026
doi: https://doi.org/10.36677/medicinainvestigacion.v11i2.20348.
Sección
Artículos de revisión
Esta obra está bajo licencia internacional Creative Commons Reconocimiento-NoComercial-SinObrasDerivadas 4.0.
Citas
Hahn J, Cook NR, Alexander EK, Friedman S, Walter J, Bubes V, Kotler G, Lee IM, Manson JE, Costenbader KH. Vitamin D and marine omega 3 fatty acid supplementation and incident autoimmune disease: VITAL randomized controlled trial. BMJ. 2022 Jan 26; 376: e066452. doi: 10.1136/bmj-2021-066452. PMID: 35082139; PMCID: PMC8791065.
Vargas-Parada L. Research round-up: autoimmune disease. Nature. 2021 Jul 1; 595 (7867): S46–7.
Breedveld, F. Therapeutic monoclonal antibodies. 2000. The Lancet; 355 (9205): 735–740.
Leavy O. The birth of monoclonal antibodies. Nat Immunol. 2016 Dec 2; 17 (1): S13–S13.
Quinteros DA, Bermúdez JM, Ravetti S, Cid A, Allemandi DA, Palma SD. The-rapeutic use of monoclonal antibodies: general aspects and challenges for drug delivery. Nanostructures Drug Deliv. 2017: 807-833.
Liu, H., Gaza-Bulseco, G., Faldu, D., Chumsae, C., & Sun, J. Heterogeneity of Mono-clonal Antibodies. 2008. Journal of Pharmaceutical Sciences; 97 (7): 2426–2447.
Bermúdez K, Hidalgo G, Mora R. Anticuerpos monoclonales biespecíficos: desarrollo, producción y uso como terapia anticancerígena. Rev Médica la Univ Costa Rica. 2019; 13 (1): 11–29.
Witjal Manuel Bermúdez Marrero, Dra. Yanelis Vizcaino Luna, Dr. William Alejandro Bermúdez Marrero Acta Médica del Centro. Lupus eritematoso sistémico. 2017; Vol. 11 No. 1 .
Dennis L. Kasper, Anthony S. Fauci, Stephen L. Hauser, Dan L. Longo, J. Larry Jameson, Joseph Loscalzo. En: María Clara Andrade. Harrison: Manual de Medicina. 19 Edición. México: McGraw-Hill, 2019. https://accessmedicina.mhmedical.com/book.aspx?bookid=2128
Honarpisheh M, Köhler P, von Rauchhaupt E, Lech M. The involvement of mi-croRNAs in modulation of innate and adaptive immunity in systemic lupus erythematosus and lupus nephritis. J Immunol Res. 2018.
Téllez Castillo N, Siachoque Jara JJ, Siachoque Jara JS, Siachoque Jara MA, Siachoque Montañez HO. Activación de la célula T, alteraciones en el lupus eritematoso sistémico, una revisión narrativa. Rev Colomb Reumatol. 2018 Jan 1; 25 (1): 38–54.
Crow MK, Olferiev M, Kirou KA. Identification of Candidate Predictors of Lupus Flare. Trans Am Clin Climatol Assoc. 2015; 126: 184.
Vincent A. Unravelling the pathogenesis of myasthenia gravis. Nat Rev Im-munol. 2002; 2: 797–804.
Daniel K, Chaves H. Miastenia gravis: fisiopatología y manejo perioperatorio Myasthenia gravis: pathophysiology and perioperative management. Rev Médica Sinerg. 2021; 6 (4): 651.
Morales López A. ARTRITIS REUMATOIDE. Rev Mèdica Costa Rica y Centro-amèrica. 2013; 607: 523–8.
Carmona L. Epidemiología de la artritis reumatoide. Rev Española Reumatol. 2002; 29 (3): 86–90.
Shah K, Cragg M, Leandro M, Reddy V. Anti-CD20 monoclonal antibodies in Systemic Lupus Erythematosus. Biologicals. 2021 Jan 1; 69: 1–14.
Tanaka Y, Tummala R. Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an over-view from clinical trials. Mod Rheumatol. 2021 Jan 2; 31 (1): 1–12.
ALderman E. Myasthenia Gravis - ClinicalKey [Internet]. 2020 [ci-ted 2022 Apr 29]. Available from: https://www.clinicalkey.es/#!/content/clinical_overview/67-s2.0-b6406d64-b6ae-4bd6-a27e-ceb496521e8d
Carretero Colomer M. Infliximab. Tra-tamiento de la artritis reumatoide. Offarm. 2008 May 1; 27 (5): 124–5.
Gómez Centeno T. Rituximab y aba-tacept en la artritis reumatoide. Reu-matol Clínica. 2009 Apr 1; 5 (1): 77–81.
Bae SC, Bass DL, Chu M, Cur-tis P, Dimelow R, Harvey L, et al. The effect of 24-week belimumab treatment withdrawal followed by treatment restart in patients with SLE: an open-label, non-randomi-sed 52-week study. Arthritis Res Ther. 2022 Dec 1; 24 (1): 1–11.
Mantegazza R, Cavalcante P. Eculi-zumab for the treatment of myas-thenia gravis. Expert Opin Biol Ther. 2020 Sep 1; 20 (9): 991–8.
Dalakas MC. Immunotherapy in myas-thenia gravis in the era of biologics. Nat Rev Neurol 2018 152. 2018 Dec 20; 15 (2): 113–24.
Dalakas MC. Progress in the thera-py of myasthenia gravis: Getting closer to effective targeted im-munotherapies. Curr Opin Neurol. 2020 Oct 1; 33 (5): 545–52.
Eter P, Ipsky EL, Van Der H Eijde EMFM, Illiam EW, Lair STC, Urst AEF, et al. Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis. https://doi.org/101056/NEJM200011303432202. 2000 Nov 30; 343 (22): 1594–602.
Tavakolpour S, Alesaeidi S, Darvi-shi M, GhasemiAdl M, Darabi-Mo-nadi S, Akhlaghdoust M, et al. A comprehensive review of rituxi-mab therapy in rheumatoid arthri-tis patients. Clin Rheumatol. 2019 Nov 1; 38 (11): 2977–94.
Vargas-Parada L. Research round-up: autoimmune disease. Nature. 2021 Jul 1; 595 (7867): S46–7.
Breedveld, F. Therapeutic monoclonal antibodies. 2000. The Lancet; 355 (9205): 735–740.
Leavy O. The birth of monoclonal antibodies. Nat Immunol. 2016 Dec 2; 17 (1): S13–S13.
Quinteros DA, Bermúdez JM, Ravetti S, Cid A, Allemandi DA, Palma SD. The-rapeutic use of monoclonal antibodies: general aspects and challenges for drug delivery. Nanostructures Drug Deliv. 2017: 807-833.
Liu, H., Gaza-Bulseco, G., Faldu, D., Chumsae, C., & Sun, J. Heterogeneity of Mono-clonal Antibodies. 2008. Journal of Pharmaceutical Sciences; 97 (7): 2426–2447.
Bermúdez K, Hidalgo G, Mora R. Anticuerpos monoclonales biespecíficos: desarrollo, producción y uso como terapia anticancerígena. Rev Médica la Univ Costa Rica. 2019; 13 (1): 11–29.
Witjal Manuel Bermúdez Marrero, Dra. Yanelis Vizcaino Luna, Dr. William Alejandro Bermúdez Marrero Acta Médica del Centro. Lupus eritematoso sistémico. 2017; Vol. 11 No. 1 .
Dennis L. Kasper, Anthony S. Fauci, Stephen L. Hauser, Dan L. Longo, J. Larry Jameson, Joseph Loscalzo. En: María Clara Andrade. Harrison: Manual de Medicina. 19 Edición. México: McGraw-Hill, 2019. https://accessmedicina.mhmedical.com/book.aspx?bookid=2128
Honarpisheh M, Köhler P, von Rauchhaupt E, Lech M. The involvement of mi-croRNAs in modulation of innate and adaptive immunity in systemic lupus erythematosus and lupus nephritis. J Immunol Res. 2018.
Téllez Castillo N, Siachoque Jara JJ, Siachoque Jara JS, Siachoque Jara MA, Siachoque Montañez HO. Activación de la célula T, alteraciones en el lupus eritematoso sistémico, una revisión narrativa. Rev Colomb Reumatol. 2018 Jan 1; 25 (1): 38–54.
Crow MK, Olferiev M, Kirou KA. Identification of Candidate Predictors of Lupus Flare. Trans Am Clin Climatol Assoc. 2015; 126: 184.
Vincent A. Unravelling the pathogenesis of myasthenia gravis. Nat Rev Im-munol. 2002; 2: 797–804.
Daniel K, Chaves H. Miastenia gravis: fisiopatología y manejo perioperatorio Myasthenia gravis: pathophysiology and perioperative management. Rev Médica Sinerg. 2021; 6 (4): 651.
Morales López A. ARTRITIS REUMATOIDE. Rev Mèdica Costa Rica y Centro-amèrica. 2013; 607: 523–8.
Carmona L. Epidemiología de la artritis reumatoide. Rev Española Reumatol. 2002; 29 (3): 86–90.
Shah K, Cragg M, Leandro M, Reddy V. Anti-CD20 monoclonal antibodies in Systemic Lupus Erythematosus. Biologicals. 2021 Jan 1; 69: 1–14.
Tanaka Y, Tummala R. Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an over-view from clinical trials. Mod Rheumatol. 2021 Jan 2; 31 (1): 1–12.
ALderman E. Myasthenia Gravis - ClinicalKey [Internet]. 2020 [ci-ted 2022 Apr 29]. Available from: https://www.clinicalkey.es/#!/content/clinical_overview/67-s2.0-b6406d64-b6ae-4bd6-a27e-ceb496521e8d
Carretero Colomer M. Infliximab. Tra-tamiento de la artritis reumatoide. Offarm. 2008 May 1; 27 (5): 124–5.
Gómez Centeno T. Rituximab y aba-tacept en la artritis reumatoide. Reu-matol Clínica. 2009 Apr 1; 5 (1): 77–81.
Bae SC, Bass DL, Chu M, Cur-tis P, Dimelow R, Harvey L, et al. The effect of 24-week belimumab treatment withdrawal followed by treatment restart in patients with SLE: an open-label, non-randomi-sed 52-week study. Arthritis Res Ther. 2022 Dec 1; 24 (1): 1–11.
Mantegazza R, Cavalcante P. Eculi-zumab for the treatment of myas-thenia gravis. Expert Opin Biol Ther. 2020 Sep 1; 20 (9): 991–8.
Dalakas MC. Immunotherapy in myas-thenia gravis in the era of biologics. Nat Rev Neurol 2018 152. 2018 Dec 20; 15 (2): 113–24.
Dalakas MC. Progress in the thera-py of myasthenia gravis: Getting closer to effective targeted im-munotherapies. Curr Opin Neurol. 2020 Oct 1; 33 (5): 545–52.
Eter P, Ipsky EL, Van Der H Eijde EMFM, Illiam EW, Lair STC, Urst AEF, et al. Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis. https://doi.org/101056/NEJM200011303432202. 2000 Nov 30; 343 (22): 1594–602.
Tavakolpour S, Alesaeidi S, Darvi-shi M, GhasemiAdl M, Darabi-Mo-nadi S, Akhlaghdoust M, et al. A comprehensive review of rituxi-mab therapy in rheumatoid arthri-tis patients. Clin Rheumatol. 2019 Nov 1; 38 (11): 2977–94.